UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease

Kimberlin, DW; Jester, PM; Sanchez, PJ; Ahmed, A; Arav-Boger, R; Michaels, MG; Ashouri, N; ... Whitley, RJ; + view all (2015) Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. Obstetrical & Gynecological Survey , 70 (8) pp. 489-490. 10.1097/01.ogx.0000470817.99322.8e. Green open access

[thumbnail of Griffiths_CASG-112-manuscript-v3.0-manuscript-clean-lrb.pdf]
Preview
Text
Griffiths_CASG-112-manuscript-v3.0-manuscript-clean-lrb.pdf

Download (298kB) | Preview

Abstract

Congenital cytomegalovirus (CMV) affects 0.6% to 0.7% of live births in industrialized nations. It is the leading viral causeof mental retardation and can also result in sensorineural hearing loss. Accepted treatment for patients with symptomatic congenital CMV involving the central nervous system includes intravenous ganciclovir, but the benefits of intravenous ganciclovir may wane over time. Oral therapy with valganciclovir has also been used in the treatment of congenital CMV, and the benefit of longer therapy was studied in this randomized controlled trial. A total of 40 sites participated in the study, and newborns were eligible if they had symptomatic congenital CMV disease, without or without central nervous system involvement. All patients received valganciclovir for 6 weeks, and 1 group continued the treatment for 4.5 months, whereas the rest received a placebo. Change in hearing in the better ear was measured as the primary end point. From 31 study sites, a total of 96 participants were randomized, with 47 participants receiving 6 months of treatment and 49 receiving placebo. A total of 12 stopped taking the blinded medication before the end of the study, but none did so because of adverse events. At 6 months, hearing in the better ear was similar between the 2 groups, with 2 having improvement in the 6-month group and 3 having improvement in the 6-week group, and 5 and 3, respectively, worsening (P = 0.41). At 12 months, total-ear hearing was more likely to be improved or remain normal in patients in the 6-month group than in the 6-week group (73% vs 57%, P = 0.001). The 6-month group scored better on the Bayley Scales of Infant and Toddler Development than did the 6-week group after 24 months on the receptive-communication scale (P = 0.003) and the language-composite scale (P = 0.004).Grade 3 or 4 neutropenia was not different in the 6-month versus the 6-week group (21% vs 27% after 6 months, P = 0.64).These findings suggest 6 months, compared with 6 weeks, of oral valganciclovir among infants with symptomatic congenital CMV disease modestly improved hearing, not in the short term, but in the long term. The prolonged treatment also appearedto improve developmental outcomes modestly.

Type: Article
Title: Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/01.ogx.0000470817.99322.8e
Publisher version: https://doi.org/10.1097/01.ogx.0000470817.99322.8e
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Obstetrics & Gynecology
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
URI: https://discovery.ucl.ac.uk/id/eprint/1554914
Downloads since deposit
112Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item